Health Canada’s Dealer’s Licence & Section 56 Explained with Benjamin Lightburn
In this episode, Sacha Hebbert sits with the CEO, Benjamin Lightburn of Filament Health, to discuss the ins and outs of being a licensed dealer of naturally derived psilocybin in Canada and internationally.
Psychedelic Spotlight Podcast · Benjamin Lightburn, Sacha Hebbert
Audio is streamed directly from the publisher (cdn.simplecast.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Filament Health produces non-synthetic psychedelic substances for research and treatment. They’re known as the first lab to have non-synthesized psilocybin for clinical trials and hope to show the efficacy of naturally derived psychedelics. Benjamin explains some current clinical trials as they test out the difference between oral and sublingual administration of psilocybin.We also dive into the Special Access Program and how to apply to Health Canada for access to non-approved drugs for experimental treatments of depression.
You can keep in touch with Benjamin on Twitter (@benlightburn) or with Filament Health on Twitter (@FilamentHealth), Instagram (@FilamentHealth), or on their website (filament.health)